Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxiglutatione. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR known ✓ | P00390 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.71 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.71 |
| ▸ | GLO1 | Q04760 | 4/20 | 0.62 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxiglutatione SCHEMBL1230605 | 1.00 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL18744121 | 0.99 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL13561367 | 0.99 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL1533892 | 0.99 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL16377441 | 0.99 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL19579378 | 0.99 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL4362052 | 0.99 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL138746 | 0.99 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL29386974 | 0.97 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL13930989 | 0.96 | PTGS1 (0.70) | PTGS1GSTK1GLO1NOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3600557-B1 | PHARMACEUTICAL COMPOSITION COMPRISING GLUTATIONE DISULFIDE AND GLUTATHIONE DISULFIDE S-OXIDE | OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTJU IVA FARM (RU) | 2021-11-03 | — | — | EP | disclosed |
| US-20210330611-A1 | THERAPY FOR NEUROLOGICAL DISEASES/DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-28 | — | — | US | disclosed |
| US-10786577-B2 | Pharmaceutical composition comprising glutatione disulfide and glutathione disulfide S-oxide | OBSCHESTVO S ORGANICHENNOY OTVETSTVENNOSTJU “IVA FARM” (RU) | 2020-09-29 | — | — | US | disclosed |
| US-20200121802-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GLUTATIONE DISULFIDE AND GLUTATHIONE DISULFIDE S-OXIDE | OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTJU "IVA FARM" (RU) | 2020-04-23 | — | — | US | disclosed |
| EP-3600557-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GLUTATIONE DISULFIDE AND GLUTATHIONE DISULFIDE S-OXIDE | Obschestvo S Ogranichennoy Otvetstvennostju "Iva Farm" (RU) | 2020-02-05 | — | — | EP | disclosed |
| CN-110740745-A | Pharmaceutical compositions containing glutathione disulfide and glutathione disulfide S-oxide | 伊娃农场有限责任公司 | 2020-01-31 | — | — | CN | disclosed |
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20140050694-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121802-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GLUTATIONE DISULFIDE AND GLUTATHIONE DISULFIDE S-OXIDE | GSS, GPX1, GSR | GSR 3/4885PTGS1 138/4885GSTK1 20/4885 |
| US-10786577-B2 | Pharmaceutical composition comprising glutatione disulfide and glutathione disulfide S-oxide | GSS, GPX1, GSR | GSR 3/4885PTGS1 138/4885GSTK1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.